NCT02505269View on ClinicalTrials.gov

Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

August 7, 2015

Primary Completion Date

June 30, 2019

Study Completion Date

June 30, 2019

Conditions
Hodgkin Lymphoma
Interventions
DRUG

Brentuximab Vedotin

DRUG

Adriamycin

DRUG

Dacarbazine

Trial Locations (2)

02114

Massachusetts General Hospital, Boston

02215

Dana Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Seagen Inc.

INDUSTRY

lead

Massachusetts General Hospital

OTHER

NCT02505269 - Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter